

RNS Number : 6806J
Futura Medical PLC
18 August 2023

18 August 2023

Futura Medical plc
("Futura" or the "Company")

Notice of Interim Results

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the pharmaceutical company developing innovative sexual health products, will announce its interim results for the six months ended 30 June 2023 on Monday 18th September 2023.

The Company will host a webcast for investors and analysts on the day of the results, which will be made available within the investor centre section of the Company's website.

A Retail Investor event is scheduled for Tuesday 19th September at 10.00am BST with Investor Meet Company. Retail Investors can register via www.investormeetcompany.com.

-ENDS-

For further information, please contact:

Futura Medical plc

James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: investor.relations@futura-medical.com
Tel: +44 (0) 1483 685 670
www.futura-medical.com

Nominated Adviser and Sole Broker:

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000

For media enquiries please contact:

Optimum Strategic Communications

Nick Bastin/ Jonathan Edwards/ Zoe Bolt/ Elena Bates
Email: futura-medical@optimumcomms.com
Tel: +44 (0) 203 882 9621

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing innovative products based on its proprietary, transdermal DermaSys® technology.

MED3000, the Company's breakthrough treatment for erectile dysfunction ("ED") has a unique evaporative mode of action and is clinically proven as an effective topical treatment for adult men with ED, with a key claim of "Helps you get an erection within 10 minutes". Eroxon® is available Over the Counter ("OTC") without a doctor's prescription. www.eroxon.com.

MED3000 is being manufactured and commercialised under the brand name Eroxon® in regulatory approved countries and is FDA approved in the US, CE marked in Europe and UKCA marked in the UK and a growing number of countries across the world. Futura has commercial agreements with the likes of Haleon for the US market and Cooper Consumer Health for Europe.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futura-medical.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORUBUUROBUWAAR